FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person*					2. 1	Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [RANI]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
<u>IMRAN MIR A</u>				100	X									Directo	r		10% Ow	ner		
(Last) (First) (Middle) C/O RANI THERAPEUTICS LLC					3. Date of Earliest Transaction (Month/Day/Year) 05/25/2022									Officer below)	(give title		Other (s below)	pecify		
2051 RINGWOOD AVE.					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SAN JOSE CA 95131													X Form filed by One Reporting Person Form filed by More than One Reporting Person					- 1		
(City)	(St	tate)	(Zip)																	
		Tab	le I - Nor	n-Deri	vativ	e Se	curities	s Ac	quired, D)isp	osed o	f, or Be	neficia	lly (Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						ear)	2A. Deemed Execution Date, if any (Month/Day/Yea		Transaction Code (Instr. 5		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			d	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	V	Amount	(A) or (D)	Price		Transact (Instr. 3 a	tion(s)			mati. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)				6. Date Exercisable Expiration Date (Month/Day/Year)		of Securities		ies g Security	Do	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	i i	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares							
Stock Option (Right to Buy)	\$10.89	05/25/2022			A		41,416		(1)	0:	5/24/2032	Class A Common Stock	41,416		\$0.00	41,410	6	D		

Explanation of Responses:

1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

Remarks:

/s/ Svai Sanford, Attorney-in-Fact for Mir Imran

05/27/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.